An Open-Label Study to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Subjects with Thrombocytopenia Scheduled for a Surgical Procedure
This Study is
No Longer Enrolling
The purpose of this study is to test the safety and effectiveness of the study drug, avatrombopag, in subjects with thrombocytopenia undergoing an operation. Patients will receive either 60mg or 80mg of avatrombopag once daily by mouth for 5 days prior to surgery
MoreAdult
Adult, undergoing surgery to critical site (i.e. spine), low platelet count prior to surgery
Can not have: history of blood clots, be on anticoagulant or antiplatelet therapy prior to surgery, alcohol dependence, active infection, significant cardiovascular disease, current malignancy, hepatic encephalopathy or hepatocellular carcinoma.
Treatment
University of Colorado Hospital
Protocol Number: 18-0546
More information available at ClinicalTrials.gov: NCT03326843
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers